Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Executive Summary

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

You may also be interested in...



Novan Still Hopeful But May Be Stranded After Phase III Molluscum Failure

Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.

Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102

After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel